Searches for wholesale tb-500 australia usually assume that the main questions are price, purity and logistics. In Australia the first question is regulatory. This reference sets out the current regulatory record, what the name TB-500 does and does not identify, and how to read the analytical documents that accompany research peptides. It is an evidence and documentation reference, not an offer of supply or a statement of availability.
The TB-500 and thymosin beta-4 evidence map brings the regulatory record and the published studies together in one place.
Key Takeaways
- TB-500 and thymosin beta-4 have been listed in Schedule 4 and Appendix D (clause 5) of the Poisons Standard since 1 June 2016; possession without the relevant authority is unlawful.
- The October 2026 Poisons Standard retains both entries, and TB-500 is not an approved medicine in Australia.
- “Research use only” labelling, business-to-business sale and wholesale quantities do not change that regulatory status.
- The name TB-500 has been used for an acetylated fragment of thymosin beta-4, so findings for the full-length protein cannot be assumed to apply to a product sold under that name.
- HPLC purity and mass-spectrometry results answer different questions, and neither establishes legal status, sterility or suitability for a study.
Regulatory Status of TB-500 in Australia
TB-500 and thymosin beta-4 have been listed in Schedule 4 and in Appendix D, clause 5, of the Poisons Standard since 1 June 2016. Appendix D clause 5 covers substances for which possession without the relevant authority is unlawful. The October 2026 Poisons Standard retains both entries. TB-500 is not an approved medicine in Australia.
A “research use only” label, a business-to-business transaction or a wholesale quantity does not create an exemption. The Therapeutic Goods Administration explains its approach in how it regulates therapeutic peptide products. Institutions considering any work with these substances should confirm the applicable authorities with their research governance team and qualified regulatory advisers before taking any step.
What the Name TB-500 Identifies
Thymosin beta-4 is a 43-amino-acid protein. The name TB-500 is used less consistently. A 2012 analytical study described a material called TB-500 as an acetylated fragment corresponding to part of thymosin beta-4 (Ac-LKKTETQ). The purpose of that work was detection in equine samples, not demonstrating a benefit (Ho et al., 2012).
For that reason, a paper on full-length thymosin beta-4 cannot be assumed to describe a product labelled TB-500. Record the sequence, molecular mass and form stated in the documentation before attributing any published finding to a specific material. The actin-binding evidence review and the cell-migration assay guide discuss how far the laboratory literature goes and where it stops.
Reading Analytical Documentation
An HPLC chromatogram reports how much of the detected signal sits in the main peak under the stated method. It is a relative purity measure, and its meaning depends on the column, gradient and detection settings. A mass-spectrometry result addresses whether the observed mass is consistent with the expected molecule. The two results answer different questions.
Neither result establishes sterility, endotoxin levels, legal status or suitability for a particular protocol. A purity percentage on a product page is a claim to be checked against a batch-specific report, not a guarantee that applies to every vial.
Matching a Report to a Batch
Check that the report names the material, states a batch or sample identifier and a test date, and identifies the testing laboratory. A report that cannot be connected to a specific batch should be recorded as an unresolved question rather than treated as confirmation. The testing standards page explains how independent reports are used on this site and what they do not show.
Batch-to-Batch Variation
Results for one batch do not describe the next. Where a study depends on consistent material, record each batch identifier and treat a change of batch as a variable to document, rather than assuming equivalence.
Storage and Stability Claims
A shelf-life cannot be inferred from the lyophilised format alone. It depends on product-specific stability evidence and the documented storage conditions for the relevant batch. Use the expiry or retest date and handling information stated in the product documentation, and keep records of receipt and storage conditions.
Transport conditions are a separate question. Whether temperature monitoring applies to a given consignment should be confirmed from documentation rather than assumed. Dispatch origin can vary and may include offshore fulfilment, as the Shipping Policy explains; estimates are not a promise of domestic dispatch.
What Wholesale Quantities Do Not Change
Multi-vial formats can make record-keeping simpler, because a known number of containers can be logged against one batch. They do not change a substance’s scheduling, create an exemption from Appendix D, or improve the quality of the material. The same documentation standard applies to one vial or many.
The supplier qualification and quality standards review covers documentation checks that apply across research peptides.
Frequently Asked Questions
Is TB-500 legal for research purposes in Australia?
TB-500 and thymosin beta-4 are listed in Schedule 4 and Appendix D (clause 5) of the Poisons Standard, so possession without the relevant authority is unlawful. Research-use wording does not change that status, and TB-500 is not an approved medicine in Australia. Institutions should confirm the applicable authorities with their research governance team and qualified regulatory advisers.
Is TB-500 the same as thymosin beta-4?
Not necessarily. The name TB-500 has been used for an acetylated fragment of thymosin beta-4, so the sequence and form need to be confirmed from documentation before findings for the full-length protein are applied to a specific product.
What do HPLC and mass-spectrometry reports show?
HPLC reports the relative purity of the main peak under the stated method; mass spectrometry addresses whether the observed mass matches the expected molecule. Neither result establishes sterility, legal status or suitability for a study, and each report should be matched to a specific batch.
Can TB-500 be used for human clinical trials?
Not on the basis of a research-use label or ordinary research supply. TB-500 is an unapproved Schedule 4 substance in Australia, and human trials require appropriate regulatory and ethics approval. Consult the TGA and your institution’s research governance team for advice specific to a proposed study.
What is the shelf life of lyophilised TB-500 vials in lab storage?
A verified shelf-life cannot be stated from the lyophilised format alone. It depends on product-specific stability evidence and the documented storage conditions for the relevant batch. Use the expiry or retest date stated in the documentation and keep records of receipt and storage.
Do wholesale quantities change the regulatory status of TB-500?
No. Scheduling and Appendix D status apply regardless of quantity, packaging or a business-to-business transaction. Multi-vial formats can simplify record-keeping but do not create an exemption.
Is a combined BPC-157 and TB-500 product supported by the evidence for each component?
No. Evidence for either component alone does not establish the effects, interactions or safety of a combination. The appropriate evidence would identify the actual combination, and the TB-500 component carries its Schedule 4 and Appendix D status in any blend.
Related from Eternal Peptides Wholesale
Eternal Peptides Wholesale publishes batch-specific Kovera Labs reports in its certificate of analysis library, so the documentation for a listed batch can be read alongside the evidence discussed in this article.
- Peptide COA library: batch-specific Kovera Labs reports with their verification details
- Our peptide testing standards: how Kovera Labs reports is used and reported
- BPC-157 and TB-500 research catalogue
- Evidence review: Peptides for muscle gain: a structured evidence review
- Evidence review: Peptides wholesale: supplier qualification and quality standards
Related reading: TB-500 for Cell Migration Assays: Design, Controls and Interpretation; TB-500 Actin-Binding Properties Research: Evidence and Limits
Testing references updated 1 November 2026 for the published Kovera Labs report set. Original research and catalogue snapshot dates remain as stated.